Nutriband Inc. (NTRB) earnings
NTRB earnings moved a median of +0.68% by the close. Quarterly and annual NTRB reports and results, each read against the price at its own news timestamp. Back to the NTRB overview →
20 measured NTRB earnings events.
Where these NTRB earnings landedvs 20 measured NTRB earnings reactions
| Middle 50% of NTRB earnings reactions | -1.23% to +2.19% |
|---|---|
| Median reaction (to close) | +0.68% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 NTRB earnings events with a measured close landed between -1.23% and +2.19%; 60% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q NutriBand Inc. For: Jul 31 | SEC filing · Form 10-Q | +0.33% | +0.33% | |
| Form 10-Q NutriBand Inc. For: Apr 30 | SEC filing · Form 10-Q | +0.28% | -3.42% | |
| Form 10-K/A NutriBand Inc. For: Jan 31 | SEC filing · Form 10-K | +0.70% | +0.29% | |
| Form 10-K NutriBand Inc. For: Jan 31 | SEC filing · Form 10-K | +0.79% | +1.98% | |
| Form 10-Q NutriBand Inc. For: Oct 31 | SEC filing · Form 10-Q | -0.63% | +5.07% | |
| Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl | Press release | -1.12% | -1.64% | |
| Form 10-Q NutriBand Inc. For: Jul 31 | SEC filing · Form 10-Q | -1.12% | -1.64% | |
| Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl | Press release | +1.58% | -1.10% | |
| Form 10-Q NutriBand Inc. For: Apr 30 | SEC filing · Form 10-Q | +1.58% | -1.10% | |
| Form 10-K/A NutriBand Inc. For: Jan 31 | SEC filing · Form 10-K | +0.00% | -0.18% | |
| Form 10-K NutriBand Inc. For: Jan 31 | SEC filing · Form 10-K | -2.86% | +1.43% | |
| Form 10-Q NutriBand Inc. For: Oct 31 | SEC filing · Form 10-Q | +8.69% | +2.84% | |
| Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025 | Press release | +8.69% | +2.84% | |
| Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025 | Press release | -2.77% | -9.36% | |
| Form 10-Q NutriBand Inc. For: Jul 31 | SEC filing · Form 10-Q | -2.77% | -9.36% | |
| Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year | Press release | +2.16% | +10.99% | |
| Form 10-Q NutriBand Inc. For: Apr 30 | SEC filing · Form 10-Q | -3.41% | +1.02% | |
| Form 10-K NutriBand Inc. For: Jan 31 | SEC filing · Form 10-K | — | +1.16% | |
| Form NT 10-K NutriBand Inc. For: Jan 31 | SEC filing · Form NT | — | +1.16% | |
| Form 10-Q NutriBand Inc. For: Oct 31 | SEC filing · Form 10-Q | — | +5.53% |
Keep exploring
More NTRB: analyst actions → · SEC filings → · NTRB overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Propanc Biopharma, Inc. (PPCB) | 144 | 0.00% | 41% |
| Cara Therapeutics, Inc. (CARA) | 143 | -0.56% | 46% |
| Redhill Biopharma Ltd. - American Depositary Shares (RDHL) | 143 | -0.50% | 39% |
| Alimera Sciences, Inc. (ALIM) | 142 | 0.00% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.